For many in the global life sciences industry, JPM Week at the start of the year in San Francisco is seen a sone of those pivotal weeks that sets the tone for the forthcoming months as investors, companies, advisors and policymakers all converge at scale around a plethora of events and activities.

One Nucleus will be delighted to be supporting our members in their endeavours to connect with their peers and instigate the deal flow that will shape their 2026. Below is a summary of the opportunities for our members:

RESI JPM

• UK has the potential to unlock £8 in socio-economic returns for every £1 spent on preventive healthcare, according to new Deloitte analysis;
• Increasing prevention spend from current 6% to 10% could lead to £42 billion of savings to the UK healthcare system in 10 years;
• A 7% reduction in preventable deaths could save over 5,400 lives annually, with a societal value of £6 billion.

The UK has the potential to unlock £8^[1] in socio-economic returns for every £1 spent on preventive healthcare, according to a new health report by Deloitte.

Cutting-edge product for stem cell research and human embryo modelling

Amsbio reports that its iMatrix-511 recombinant laminin product has been cited in a recent paper** from researchers at the Stanford University School of Medicine, Stanford, CA, USA as a pivotal tool for stem cell culture and blastoid formation.

Become a mentor on Beacon’s Patient Group Mentoring Programme and make a real difference to the rare disease community!

Mentees need support across a wide range of areas, from charity management and fundraising to communications, life sciences and more.

You don’t need a background in rare diseases to have something valuable to offer.

As a mentor, you will:

• Be paired with a rare disease patient group leader for a 12-month partnership

• Grow your leadership skills and aid your professional development

Enedra Therapeutics (Enedra), a pioneering biotechnology company focused on developing novel treatments for genetically heterogeneous cancers, today announced the appointment of Adrian Ibrahim, PhD, MBA, as its new Chief Executive Officer. Dr Ibrahim will also join the Company’s Board of Directors. His appointment comes as Enedra prepares to initiate its seed phase fundraising round.